Home›Stock Screener›Fredun Pharmaceuticals

Fredun Pharmaceuticals Share Price Today | Stock Price & Fredun Pharmaceuticals Share Screener

FREDUN Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1636.40
▲ 64.40 (4.10%)
2026-11-18 00:00:00
Live Share Price BSE
₹1634.25
▲ 60.70 (3.86%)
2026-11-18 00:00:00

As of November 18, 2026, the live Fredun Pharmaceuticals share price (NSE: FREDUN) is ₹1,636.40 on NSE and ₹1,634.25 on BSE, up 4.10% from the previous close, with shares trading between ₹1,585.00 and ₹1,641.00 in today's trading session, and a 52-week range of ₹1,221.60–₹1,636.40. Track FREDUN market capitalization to gauge the company's total market size. Use the Fredun Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Fredun Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹266 and net income of ₹19, with EBITDA of ₹41, an operating margin of 15.0% and a profit margin of 7.1%.

Fredun Pharmaceuticals Market Cap ₹2,596.48 Cr.
FREDUN P/E Ratio (TTM) 48.10
Fredun Pharmaceuticals P/B Ratio 7.10
EPS (TTM) ₹66.81
Dividend Yield 0.05%
Debt to Equity 0.93
FREDUN 52 Week High ₹1636.40
Fredun Pharmaceuticals 52 Week Low ₹1221.60
Operating Margin 15.00%
Profit Margin 7.14%
FREDUN Revenue (TTM) ₹266.00
EBITDA ₹41.00
Net Income ₹19.00
Total Assets ₹642.00
Total Equity ₹278.00

Fredun Pharmaceuticals Share Price Chart

Track the current stock price of Fredun Pharmaceuticals with an interactive chart. Analyse FREDUN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Fredun Pharmaceuticals stock quote in one place.

The quote of ₹1,636.40 sits between the 52-week low of ₹1,221.60 and the 52-week high of ₹1,636.40, and the latest session moved 4.10% from the previous close.

Fredun Pharmaceuticals Company Profile - Fundamental Screener

Screen Fredun Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for FREDUN shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE194R01017.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE194R01017

Fredun Pharmaceuticals Balance Sheet Screener

Screen FREDUN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹642, up from ₹487 in 2025.

Latest statistics put total assets at ₹642 and shareholder funds at ₹278, with a leverage ratio of 0.93.

Item 2026 2025

Assets

Total Assets 642 487
Current Assets 0 0
Fixed Assets 118 53

Liabilities

Total Liabilities 0 0
Current Liabilities 67 18
Non-Current Liabilities 0 0

Shareholders' Equity

Total Equity 278 141
Share Capital 6 5
Reserves & Surplus 259 137

Fredun Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Fredun Pharmaceuticals income statement and profit fundamentals. Analyze FREDUN quarterly results. Fredun Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹266 and net profit was ₹19, equal to earnings per unit of ₹10.99, at an operating margin of 15%.

In that period expenses were ₹225, interest cost ₹9 and tax ₹11. The next period listed, 2026-Jun, shows revenue of ₹228 and net profit of ₹13.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun

Revenue and Expenses

Revenue 266 228 210 160 144 119 165 286 0 0
Expenses 225 196 184 135 123 103 150 251 0 0

Operating Costs and Margins

EBITDA 41 32 26 25 21 17 15 35 0 0
Operating Profit % 15.00% 14.00% 12.00% 16.00% 14.00% 14.00% 9.00% 12.00% 0.00% 0.00%
Depreciation 4 4 3 2 2 1 2 3 0 0
Interest 9 9 15 11 8 7 8 14 0 0

Profit and Earnings

Profit Before Tax 30 21 11 14 13 9 7 20 0 0
Tax 11 7 1 4 3 2 1 7 0 0
Net Profit 19 13 11 11 9 7 6 14 0 0
EPS 10.99 23.82 19.70 22.19 19.98 14.33 12.71 29.09 0.00 0.00

Fredun Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen FREDUN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹12, and net cash flow was an inflow of ₹60.

Over the same period, investing activities used ₹74 and financing activities provided ₹121.

Item 2026-March 2025-March

Cash from Operations and Investing

Operating Activities 12 -17
Investing Activities -74 -6

Financing and Net Cash

Financing Activities 121 27
Net Cash Flow 60 4

Fredun Pharmaceuticals Shareholding Pattern Screener

See Fredun Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Fredun Pharmaceuticals promoter holding and ownership changes for FREDUN on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Feb, promoters held 43.06%, foreign institutions 1.06%, domestic institutions 2.89% and the public 45.63%, spread across 8,443 shareholders.

The shareholder count was 8,443 in 2026-Feb, compared with 8,400 in 2026-Mar.

Item 2026-Feb 2026-Mar 2026-Jun 2026-Jul 2026-Sept 2025-Mar 2025-Jun 2025-Sept

Promoter Holding

Promoter Holding 43.06% 44.17% 44.57% 44.57% 43.62% 48.93% 48.93% 48.93%

Institutional Investors

FII Holding 1.06% 1.06% 1.06% 1.06% 0.69% 0.00% 0.00% 0.01%
DII Holding 2.89% 2.83% 2.94% 2.94% 3.44% 1.59% 1.59% 1.60%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 45.63% 44.66% 43.79% 43.62% 43.24% 44.50% 44.52% 43.74%
Other Holding 7.37% 7.28% 7.65% 7.81% 9.01% 4.98% 4.96% 5.72%
Shareholder Count 8,443 8,400 8,903 9,598 13,502 7,976 7,906 8,120

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Fredun Pharmaceuticals. Fredun Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.70 per unit for 2026-March, a yield of 0.05%, compared with ₹0.70 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.70, ₹0.70 and ₹0.70 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.70 0.05%
2025-March ₹0.70 0.13%
2024-March ₹0.70 0.31%
2023-March ₹0.70 0.29%
2022-March ₹0.70 0.27%
2021-March ₹0.70 0.23%
2020-March ₹0.66 0.43%
2019-March ₹0.65 1.67%
2018-March ₹1.00 0.71%
2017-March ₹0.60 1.26%

Fredun Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Fredun Pharmaceuticals stock. Check FREDUN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Fredun Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Fredun Pharmaceuticals Market Events Screener - Corporate Actions

Get Fredun Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Fredun Pharmaceuticals stock events that may affect FREDUN share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Quarterly Result Announcement dated August 5, 2026 and Bonus dated July 16, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 10.43%
2026-08-05 2026-08-05 Quarterly Result Announcement NA 22.33%
2026-07-16 2026-07-16 Bonus 2:1 7.27%
2026-06-30 2026-06-30 Annual General Meeting NA 18.48%
2026-06-23 2026-06-23 Dividend ₹ 0.70 /share 1.92%
2026-05-25 2026-05-25 Quarterly Result Announcement NA 5.79%
2026-02-16 2026-02-16 Extraordinary General Meeting NA 21.57%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 10.64%
2025-11-08 2025-11-08 Quarterly Result Announcement NA -9.98%
2025-10-22 2025-10-22 Extraordinary General Meeting NA 27.12%
2025-09-30 2025-09-30 Annual General Meeting NA 8.06%
2025-09-23 2025-09-23 Dividend ₹ 0.70 /share 57.68%
2025-07-30 2025-07-30 Quarterly Result Announcement NA 11.44%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 6.41%
2025-02-04 2025-02-04 Quarterly Result Announcement NA 3.02%

Fredun Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen FREDUN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 450,451 40.80 61,674 12.69% 11,565 59.98
Divis Laboratories 295,082 87.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 177,620 85.00 13,886 20.34% 2,138 49.31
Laurus Labs 123,272 89.90 6,868 22.01% 890 49.19
Zydus Life Science 120,070 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,403 41.80 35,059 3.90% 4,158 69.34
Cipla 112,373 39.50 29,045 2.24% 3,870 55.82
Mankind Pharma 108,804 47.90 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,453 25.80 34,145 5.56% 3,503 60.38
Lupin 89,579 17.30 29,039 26.75% 5,356 44.23

Fredun Pharmaceuticals Company Announcements - News & Reports Screener

Screen FREDUN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 17, 2026 and November 17, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-17 Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting Dated 14.11.2026 -
2026-11-17 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-11-17 Statement Of Deviation Or Variation For The Quarter Ended September 30 2026. -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-06 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-05 Revised Outcome Of The Board Meeting -
2026-11-05 Revised Outcome Of The Board Meeting -
2026-11-05 Approved The Proposal For Making An Application To National Stock Exchange Of India Limited (NSE) For Listing And Trading Of The Equity Shares Of The Company On NSE. -
2026-11-05 Financial Results For The Quarter Ended 30Th September 2026. -
2026-11-05 Board Meeting Outcome for Outcome Of The Board Meeting -
2026-10-31 Board Meeting Intimation for The Company To Be Held On Thursday 05Th November 2026 -
2026-10-23 Announcement under Regulation 30 (LODR)-Allotment -
2026-10-23 Board Meeting Outcome for Outcome Of Board Meeting Dated 23Rd October 2026 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-08 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-05 Announcement under Regulation 30 (LODR)-Allotment -
2026-10-05 Revised Outcome Of Board Meeting Dated 03Rd October 2026. -
2026-10-03 Announcement under Regulation 30 (LODR)-Allotment -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,636.40, within a 52-week range of ₹1,221.60 to ₹1,636.40. The P/E ratio is 48.10 and the P/B ratio is 7.10, with earnings per unit of ₹66.81. Market capitalisation stands at ₹2,596.48 Cr and the dividend yield is 0.05%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 2 balance sheet periods, 10 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.